Elevara Medicines has dosed the first patient in its phase 2b START-SYNERGY trial, marking a key step in the development of ELV001, an oral CDK4/6 inhibitor being studied for rheumatoid arthritis in patients who do not respond sufficiently to methotrexate and TNF inhibitors.
The randomised, placebo-controlled study will enrol around 180 patients across nine countries, with recruitment already underway in North America and South Africa. Additional European sites are expected to open later in the year.
The trial builds on earlier studies showing ELV001 was well tolerated and demonstrated early signs of clinical activity.
The study will evaluate ELV001 as an add-on therapy to standard treatment, with the primary endpoint being change in DAS28-CRP at week 12, a validated measure of rheumatoid arthritis disease activity.
Emma Tinsley, Chief Executive Officer of Elevara Medicines, said: “Dosing the first patient in START-SYNERGY marks an important milestone for Elevara and the clinical development of ELV001, since we raised our $70m Series A in October 2025.
Despite significant therapeutic advances, many patients continue to experience active disease even after treatment with multiple immune-targeted therapies.”
She added: “ELV001 was developed to target mechanisms that may contribute to persistent synovial pathology and to be used alongside existing treatments. We believe this study will provide important insights into whether targeting these pathways can improve outcomes for RA patients.”
Interest is growing in the role of tissue-resident stromal cells in chronic inflammatory diseases, with evidence suggesting rheumatoid arthritis may be driven not only by immune cells but also by pathological stromal cells within the joint. ELV001 selectively inhibits CDK4/6, signalling pathways that regulate synovial fibroblast proliferation and inflammatory activity.
Professor Dominique Baeten, Chief Medical Officer of Elevara Medicines, explained: “Even with modern biologic therapies, a substantial proportion of patients continue to have active disease. Synovial fibroblasts are increasingly recognised as active contributors to disease persistence in RA. START-SYNERGY will evaluate whether ELV001 can provide a new therapeutic approach for patients who have not achieved adequate response to existing treatments.”
